Bernstein Sticks to Their Hold Rating for XPeng, Inc. Class A (9868)
In a report released yesterday, Eunice Lee from Bernstein maintained a Hold rating on XPeng, Inc. Class A (9868 – Research Report). The company's shares closed today at HK$80.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Lee is a 5-star analyst with an average return of 20.6% and a 69.81% success rate. Lee covers the Consumer Cyclical sector, focusing on stocks such as Geely Automobile Holdings, BYD Co, and Nio.
XPeng, Inc. Class A has an analyst consensus of Moderate Buy, with a price target consensus of HK$97.58.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Jim Cramer Notes PayPal (PYPL)'s CEO Alex Chriss 'Will Get You Where You Have to Go'
We recently published a list of . In this article, we are going to take a look at where PayPal Holdings, Inc. (NASDAQ:PYPL) stands against other stocks that Jim Cramer discusses. When a caller asked Cramer about PayPal Holdings, Inc. (NASDAQ:PYPL) during Mad Money's lightning round, he replied: 'Alright, listen to me, listen to me, sunshine. Alex Chriss is really coming, he did not deliver in a couple of quarters. I now think he is ready to roll. I like the stock of PayPal. It is a crowded space, admittedly, crowded space, and you know, there's a lot of companies that are trying to do the, somewhat of the same thing, including Affirm. But I will tell you that I think Alex Chriss, he'd be the man, and he will get you where you have to go.' A consumer in a cafe paying for goods using a mobile payment app. PayPal Holdings, Inc. (NASDAQ:PYPL) offers a digital payments platform that connects consumers and merchants, enabling transactions across various channels using multiple funding sources, including cards, bank accounts, and cryptocurrencies. During the April 17 episode of Squawk on the Street, Cramer mentioned the company along with a couple of others, and here is what he had to say: 'People should know that it's PayPal, Stripe, Square, all against them. And I think that these guys could be very powerful versus those. PayPal, if you remember, it's kind of dropping back a little. Square's had a little bit of problems. Stripe is on fire. Maybe this is against Stripe.' READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Jim Cramer Holds Back on GoodRx (GDRX)
We recently published a list of . In this article, we are going to take a look at where GoodRx Holdings, Inc. (NASDAQ:GDRX) stands against other stocks that Jim Cramer discusses. Noting that Cramer has not said anything about GoodRx Holdings, Inc. (NASDAQ:GDRX) in a long time, a caller asked about the company. In response, Cramer said: 'Sometimes, like my Nana Mary said, if you don't have anything good to say about someone, don't say it at all.' A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. GoodRx (NASDAQ:GDRX) provides tools that help people find lower prices on prescription drugs, along with subscriptions, telehealth services, and healthcare solutions for both humans and pets. In 2022, when a caller asked about the company during a lightning round, Cramer said, 'These are all no-go. They're in a no-fly zone. You've just got to look at it like that.' For context, GDRX stock has gone down more than 82% since the comment was aired. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
